Yumi Ito

Yumi Ito

Auto-generated profile, based on publicly available information

Yumi Ito

Department of Health Promotion Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2020 in Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
KKKeiko Kabasawa
Keiko Kabasawa
JTJunta Tanaka
Junta Tanaka
KNKazutoshi Nakamura
Kazutoshi Nakamura
YIYumi Ito
Yumi Ito
KYKinya Yoshida
Kinya Yoshida
INIchiei Narita
Ichiei Narita
Background: Evidence for primary prevention of chronic kidney disease (CKD) is insufficient. The population-based prospective Uonuma CKD cohort study aims to explore associations of lifestyle and other risk factors with CKD. We report here the study design and baseline profiles.Methods: All 67,322 residents aged ≥40 years in Minamiuonuma City, Uonuma City, and Yuzawa Town, Niigata Prefecture, Japan and 11,406 who attended local health-check examinations were targeted for baseline questionnaire and biochemical sampling, respectively. Information was gathered from 43,217 (64.2%) questionnaires and 8,052 (70.6%) biochemical samples; 6,945 participants consented to both questionnaire and biochemical sampling at baseline, conducted between fiscal 2012 and 2015. Participants provided information regarding sociodemographic, lifestyle, and self-reported outcomes. Urine albumin-to-creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR) were measured. The primary outcome is CKD based on self-report and biochemical/clinical diagnosis.Results: Mean (standard deviation) age of questionnaire respondents was 63.3 (12.5) years for men and 64.3 (13.3) years for women. Among participants who submitted urine samples, median ACR (interquartile range; IQR) was 10.0 (5.0-24.0) mg/g for men and 13.0 (7.7-27.0) mg/g for women, and median eGFR (IQR) was 73.6 mL/min/1.73 m2 (63.5-84.5) for men and 73.5 mL/min/1.73m2 (64.4-83.5) for women. ACR 30 mg/g or more was found in 1,741 participants (21.7%) and eGFR <60 mL/min/1.73 m2 in 1,361 participants (16.9%).Conclusion: The Uonuma CKD cohort study was established to investigate the impact of lifestyle on CKD development and to provide data for preventing the onset and progression of CKD.

15 January 2022 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
KKKeiko Kabasawa
Keiko Kabasawa
MHMichihiro Hosojima
Michihiro Hosojima
YIYumi Ito
Yumi Ito
KMKazuo Matsushima
Kazuo Matsushima
JTJunta Tanaka
Junta Tanaka
ASAkihiko Saito
Akihiko Saito
Although metabolic syndrome traits are risk factors for chronic kidney disease, few studies have examined their association with urinary biomarkers. Urinary biomarkers, including A-megalin, C-megalin, podocalyxin, albumin, α1-microglobulin, β2-microglobulin, and N-acetyl-β-D-glucosaminidase, were cross-sectionally assessed in 347 individuals (52.7% men) with a urine albumin-to-creatinine ratio (ACR) < 300 mg/g in a health checkup. Metabolic syndrome traits were adopted from the National Cholesterol Education Program (third revision) of the Adult Treatment Panel criteria modified for Asians. Participants had a mean body mass index, estimated glomerular filtration rate (eGFR), and median ACR of 23.0 kg/m2, 74.8 mL/min/1.73 m2, and 7.5 mg/g, respectively. In age- and sex-adjusted logistic regression analysis, A-megalin and albumin were significantly associated with the clustering number of metabolic syndrome traits (3 or more). After further adjustment with eGFR, higher quartiles of A-megalin and albumin were each independently associated with the clustering number of metabolic syndrome traits (adjusted odds ratio for A-megalin: 1.30 per quartile, 95% CI 1.03–1.64; albumin: 1.42 per quartile, 95% CI 1.12–1.79). Both urinary A-megalin and albumin are associated with the clustering number of metabolic syndrome traits. Further research on urinary A-megalin is warranted to examine its role as a potential marker of kidney damage from metabolic risk factors.